Pharmacology
All Targets
7-TM Receptors
Ion Channels
Nuclear Receptors
Enzyme-Linked Receptors
Transporters
Enzymes
Other Pharmacology
Cellular Processes
Angiogenesis
Apoptosis
Cell Cycle
Cell Metabolism
Cytoskeleton & Motor Proteins
ECM & Adhesion Molecules
Epigenetics
Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
Post-translational Modification
More Information »Post-translational modifications are chemical changes to a protein that occur after translation widening the range of functions of the final protein. Many modifications occur in the RER (rough endoplasmic reticulum). There are five types of post-translational modification.
Post-Translational Modification Products
Inhibitors |
|
Cat.No. |
Product Name / Activity |
| 4200 | C 646 |
| Selective p300/CBP inhibitor | |
| 3416 | Tris DBA |
| N-myristoyltransferase-1 inhibitor; antiproliferative | |
| 2406 | FTI 276 |
| Farnesyltransferase (FTase) inhibitor; antitumor | |
| 2407 | FTI 277 |
| Prodrug form of FTI 276 (Cat. No. 2406) | |
| 2430 | GGTI 298 |
| Geranylgeranyltransferase I (GGTase I) inhibitor | |
| 2637 | Gliotoxin |
| Farnesyltransferase and geranylgeranyltransferase I inhibitor | |
| 4294 | LB 42708 |
| Selective farnesyltransferase (FTase) inhibitor | |
| 2978 | PYR 41 |
| Ubiquitin-activating enzyme (E1) inhibitor | |




